Oxford Biomedica (OXB) Stock Overview
A contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for OXB from our risk checks.
OXB Community Fair Values
Create NarrativeSee what 32 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Oxford Biomedica plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£5.75 |
| 52 Week High | UK£9.62 |
| 52 Week Low | UK£3.06 |
| Beta | 1.09 |
| 1 Month Change | -3.04% |
| 3 Month Change | -12.75% |
| 1 Year Change | 76.11% |
| 3 Year Change | 22.60% |
| 5 Year Change | -49.91% |
| Change since IPO | -77.23% |
Recent News & Updates
Narrative Update • May 20
OXB: Future Upside Will Depend On Fast Track Execution Success
Analysts have adjusted their price target on Oxford Biomedica to reflect updated assumptions on discount rate, revenue growth, profit margins and future P/E. The latest Street research has resumed coverage with a supportive stance on the stock and its long term value potential around £8.43.
Narrative Update • May 03
OXB: Future Cash Generation And Execution Risks Will Shape Balanced Outlook
Analysts have lifted their price target on Oxford Biomedica to £5.50, citing updated assumptions on discount rate, revenue growth, profit margin and future P/E that support a more refined view of the stock’s risk and earnings profile. Analyst Commentary Recent research coverage frames Oxford Biomedica as an opportunity with a refreshed risk and earnings profile, but not all commentary is uniformly positive.Narrative Update • Apr 19
OXB: Future Performance Will Reflect Fast Track Platform Execution Success
Analysts have lifted their price target for Oxford Biomedica from £6.67 to £8.43, citing updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E that align with recent Street research support. Analyst Commentary Bullish Takeaways Bullish analysts see the resumed coverage as a sign that Oxford Biomedica is now better aligned with current sector assumptions on revenue growth and profitability, which feeds directly into the higher fair value estimate.
Narrative Update • Apr 04
OXB: Post Transition Buy Ratings Will Support Higher Quality Business Perception
Analysts have increased the updated fair value estimate for Oxford Biomedica from £9.50 to £11.70 per share, citing recent Buy ratings and higher price targets that reflect expectations for a higher quality business following the company’s transition. Analyst Commentary Recent research indicates that bullish analysts are becoming more constructive on Oxford Biomedica, with fresh Buy ratings and higher price objectives supporting the updated fair value estimate.Recent updates
Narrative Update • May 20
OXB: Future Upside Will Depend On Fast Track Execution Success
Analysts have adjusted their price target on Oxford Biomedica to reflect updated assumptions on discount rate, revenue growth, profit margins and future P/E. The latest Street research has resumed coverage with a supportive stance on the stock and its long term value potential around £8.43.Narrative Update • May 03
OXB: Future Cash Generation And Execution Risks Will Shape Balanced Outlook
Analysts have lifted their price target on Oxford Biomedica to £5.50, citing updated assumptions on discount rate, revenue growth, profit margin and future P/E that support a more refined view of the stock’s risk and earnings profile. Analyst Commentary Recent research coverage frames Oxford Biomedica as an opportunity with a refreshed risk and earnings profile, but not all commentary is uniformly positive.Narrative Update • Apr 19
OXB: Future Performance Will Reflect Fast Track Platform Execution Success
Analysts have lifted their price target for Oxford Biomedica from £6.67 to £8.43, citing updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E that align with recent Street research support. Analyst Commentary Bullish Takeaways Bullish analysts see the resumed coverage as a sign that Oxford Biomedica is now better aligned with current sector assumptions on revenue growth and profitability, which feeds directly into the higher fair value estimate.Narrative Update • Apr 04
OXB: Post Transition Buy Ratings Will Support Higher Quality Business Perception
Analysts have increased the updated fair value estimate for Oxford Biomedica from £9.50 to £11.70 per share, citing recent Buy ratings and higher price targets that reflect expectations for a higher quality business following the company’s transition. Analyst Commentary Recent research indicates that bullish analysts are becoming more constructive on Oxford Biomedica, with fresh Buy ratings and higher price objectives supporting the updated fair value estimate.Narrative Update • Mar 21
OXB: Upgraded Rating Will Likely Expose Transition Risks In Execution
Analysts have raised their price target for Oxford Biomedica to £7.35 from £3.80. They cite the company's transition to what they view as a higher quality business as a key driver for the change.Narrative Update • Mar 06
OXB: Higher Rating Will Likely Magnify Execution And Funding Risks
Analysts have lifted their price target on Oxford Biomedica from £3.80 to £7.35, citing a higher quality business profile following the company's transition and reflecting this in updated fair value, discount rate, revenue growth, profit margin and future P/E assumptions. Analyst Commentary The latest research points to a clearer view of Oxford Biomedica's equity story, with a higher price target of 735 GBp set alongside the view that the business profile has improved following its transition.Narrative Update • Feb 20
OXB: Transition Progress And Buy Rating Will Support Higher Perceived Business Quality
Analysts have modestly trimmed their fair value estimate for Oxford Biomedica from £9.70 to £9.50, citing updated assumptions on discount rates, margins and future P/E. Some now see a higher quality business that supports a Buy rating and a higher £7.35 price target on the shares.Narrative Update • Feb 06
OXB: Upgraded Rating Will Likely Expose Vulnerable Execution Assumptions
Analysts have lifted their price target on Oxford Biomedica to £7.35 from £3.80, citing a higher quality business following the company's transition and reflecting modest tweaks to the discount rate, revenue growth and profit margin assumptions, along with a slightly lower future P/E multiple. Analyst Commentary Recent research points to a business that analysts view as higher quality following Oxford Biomedica's transition, with the new £7.35 price target reflecting updated assumptions on discount rate, revenue and margin profiles, and a revised future P/E multiple.Narrative Update • Jan 23
OXB: Upgraded Outlook Will Likely Expose Fragile Profitability Assumptions
Analysts have lifted their price target on Oxford Biomedica to £7.35 from £3.80, citing a higher quality business mix after the company’s transition and updated assumptions around revenue growth, profit margins and future P/E. Analyst Commentary Recent research highlights a shift in how the market is framing Oxford Biomedica.Narrative Update • Jan 09
OXB: Transition Progress Will Drive Rerated Business Quality And Higher Confidence
Analysts lifted their price target on Oxford Biomedica to £7.35 from £3.80 after updating their fair value estimate and assumptions on the discount rate, revenue growth, profit margin and future P/E, reflecting increased confidence in the company’s transition and business quality. Analyst Commentary Recent research shows a clear shift in sentiment toward Oxford Biomedica, with bullish analysts pointing to a higher-quality business profile following the company’s transition.Analysis Article • Dec 30
Revenues Working Against Oxford Biomedica plc's (LON:OXB) Share Price
With a price-to-sales (or "P/S") ratio of 4.9x Oxford Biomedica plc ( LON:OXB ) may be sending bullish signals at the...Narrative Update • Dec 25
OXB: Higher Price Outlook Will Likely Expose Execution And Margin Weakness
Analysts have raised their price target on Oxford Biomedica to 970 GBp from 930 GBp, reflecting improved growth expectations despite a slightly higher discount rate and modestly lower projected profit margins. Analyst Commentary While the latest target price increase signals confidence in Oxford Biomedica's long term prospects, some Bearish analysts continue to flag risks around execution, profitability, and valuation.Narrative Update • Dec 11
OXB: Future Performance Will Reflect US Capacity Expansion And Margin Execution Risks
Analysts have raised their price target on Oxford Biomedica to 970 GBp from 930 GBp, reflecting slightly stronger expectations for long term revenue growth and profit margins, while maintaining a broadly similar valuation multiple outlook. Analyst Commentary Analysts describe the higher price target as a reflection of improving confidence in Oxford Biomedica's ability to scale its revenue base and gradually enhance operating leverage, while still acknowledging execution risks in a competitive cell and gene therapy landscape.Narrative Update • Nov 27
OXB: Future Performance Will Balance Revenue Momentum With Margin Execution Risks
Narrative Update on Oxford Biomedica Analysts have raised their price target for Oxford Biomedica by £0.55 to £6.48. This change reflects improved profit margin expectations and is reinforced by recent optimistic research updates.Narrative Update • Sep 13
CDMO Expansion Will Widen Global Cell And Gene Therapy Access
Analysts have raised Oxford Biomedica’s price target from £5.55 to £5.93, citing improved growth prospects, commercial execution, and operational strength, with ongoing share price weakness seen as a potential entry point despite lingering market uncertainties and execution risks. Analyst Commentary Bullish analysts cite an improved growth outlook and enhanced commercial execution as key drivers for the upward price target revision.Analysis Article • Sep 12
Investors Still Aren't Entirely Convinced By Oxford Biomedica plc's (LON:OXB) Revenues Despite 35% Price Jump
Oxford Biomedica plc ( LON:OXB ) shares have continued their recent momentum with a 35% gain in the last month alone...Narrative Update • Aug 27
CDMO Expansion Will Widen Global Cell And Gene Therapy Access
Analysts have raised Oxford Biomedica’s price target from £5.08 to £5.40, citing strong commercial execution and improving fundamentals despite some concerns over market visibility and client demand. Analyst Commentary Bullish analysts highlight Oxford Biomedica’s strong commercial track record and operational excellence as underpinning their positive outlook.Analysis Article • Jul 29
Oxford Biomedica plc's (LON:OXB) Price Is Right But Growth Is Lacking After Shares Rocket 30%
Despite an already strong run, Oxford Biomedica plc ( LON:OXB ) shares have been powering on, with a gain of 30% in the...New Narrative • May 09
CDMO Expansion Will Widen Global Cell And Gene Therapy Access
Expansion into AAV and other vector types reduces dependency risks and supports earnings growth through diversified revenue streams.Analysis Article • Apr 10
Health Check: How Prudently Does Oxford Biomedica (LON:OXB) Use Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analysis Article • Feb 28
Oxford Biomedica plc (LON:OXB) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough
The Oxford Biomedica plc ( LON:OXB ) share price has fared very poorly over the last month, falling by a substantial...Analysis Article • Oct 19
Is Oxford Biomedica (LON:OXB) Using Debt Sensibly?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analysis Article • Aug 23
Oxford Biomedica plc (LON:OXB) Not Doing Enough For Some Investors As Its Shares Slump 28%
The Oxford Biomedica plc ( LON:OXB ) share price has fared very poorly over the last month, falling by a substantial...Shareholder Returns
| OXB | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -8.1% | -2.3% | -0.3% |
| 1Y | 76.1% | 21.9% | 18.4% |
Return vs Industry: OXB exceeded the UK Biotechs industry which returned 21.9% over the past year.
Return vs Market: OXB exceeded the UK Market which returned 18.4% over the past year.
Price Volatility
| OXB volatility | |
|---|---|
| OXB Average Weekly Movement | 6.0% |
| Biotechs Industry Average Movement | 9.2% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in GB Market | 11.8% |
| 10% least volatile stocks in GB Market | 3.2% |
Stable Share Price: OXB has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: OXB's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 977 | Frank Mathias | www.oxb.com |
Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its LentiVector platform technology is a lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems; InAAVate, a proprietary ‘plug and play’ dual-plasmid system for transient transfection, as well as a standard triple transfection system for AAV-based gene therapies. The company collaborates with pharmaceutical and biotechnology companies providing viral vector development and manufacturing services in lentivirus, adeno-associated virus, adenoviral vectors, and other viral vector types.
Oxford Biomedica plc Fundamentals Summary
| OXB fundamental statistics | |
|---|---|
| Market cap | UK£744.87m |
| Earnings (TTM) | -UK£30.13m |
| Revenue (TTM) | UK£168.74m |
4.1x
P/S Ratio-23.1x
P/E RatioIs OXB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OXB income statement (TTM) | |
|---|---|
| Revenue | UK£168.74m |
| Cost of Revenue | UK£102.76m |
| Gross Profit | UK£65.98m |
| Other Expenses | UK£96.11m |
| Earnings | -UK£30.13m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.25 |
| Gross Margin | 39.10% |
| Net Profit Margin | -17.85% |
| Debt/Equity Ratio | 45.4% |
How did OXB perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/02 17:46 |
| End of Day Share Price | 2026/06/02 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Oxford Biomedica plc is covered by 11 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kane Slutzkin | Deutsche Bank |
| Susie Jana | Edison Investment Research |
| Jens Lindqvist | Investec Bank plc (UK) |